| Primary |
| Drug Use For Unknown Indication |
39.9% |
| Pulmonary Tuberculosis |
17.4% |
| Tuberculosis |
7.9% |
| Product Used For Unknown Indication |
5.4% |
| Endocarditis |
4.6% |
| Staphylococcal Infection |
2.7% |
| Disseminated Tuberculosis |
2.5% |
| Osteitis |
2.5% |
| Osteomyelitis |
2.3% |
| Prophylaxis |
2.0% |
| Diabetes Mellitus |
1.5% |
| Hypertension |
1.5% |
| Infection |
1.5% |
| Pneumonia Legionella |
1.4% |
| Atypical Mycobacterial Infection |
1.2% |
| Streptococcal Infection |
1.2% |
| Arthritis Bacterial |
1.1% |
| Lung Transplant |
1.1% |
| Meningitis |
1.1% |
| Sepsis |
1.1% |
|
| Thrombocytopenia |
11.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
8.4% |
| Renal Failure |
6.9% |
| Neutropenia |
6.1% |
| Vomiting |
6.1% |
| Pyrexia |
5.3% |
| Toxic Skin Eruption |
5.3% |
| Acute Hepatic Failure |
4.6% |
| Hepatitis Fulminant |
4.6% |
| Jaundice |
4.6% |
| Renal Failure Acute |
4.6% |
| Anaemia |
3.8% |
| Hepatic Failure |
3.8% |
| Pancreatitis |
3.8% |
| Rash |
3.8% |
| Rash Maculo-papular |
3.8% |
| Visual Field Defect |
3.8% |
| Hepatitis Cholestatic |
3.1% |
| Nephrotic Syndrome |
3.1% |
| Pancreatitis Acute |
3.1% |
|
| Secondary |
| Tuberculosis |
16.0% |
| Drug Use For Unknown Indication |
15.2% |
| Pulmonary Tuberculosis |
9.9% |
| Product Used For Unknown Indication |
8.0% |
| Endocarditis |
6.9% |
| Disseminated Tuberculosis |
6.8% |
| Hiv Infection |
5.3% |
| Atypical Mycobacterial Infection |
3.3% |
| Arthritis Bacterial |
3.0% |
| Staphylococcal Infection |
3.0% |
| Antifungal Prophylaxis |
2.7% |
| Anxiety |
2.5% |
| Infection |
2.5% |
| Pneumonia |
2.4% |
| Prophylaxis |
2.3% |
| Extrapulmonary Tuberculosis |
2.2% |
| Antibiotic Therapy |
2.1% |
| Osteitis |
2.1% |
| Bronchopulmonary Aspergillosis |
2.0% |
| Meningitis Tuberculous |
1.9% |
|
| Drug Rash With Eosinophilia And Systemic Symptoms |
13.6% |
| Toxic Skin Eruption |
11.2% |
| Renal Failure Acute |
9.7% |
| Neutropenia |
8.3% |
| Thrombocytopenia |
6.3% |
| Liver Disorder |
5.8% |
| Vomiting |
5.8% |
| Rash Maculo-papular |
4.9% |
| Cytolytic Hepatitis |
3.9% |
| Renal Impairment |
3.9% |
| Anaemia |
3.4% |
| Hepatitis Fulminant |
2.9% |
| Interstitial Lung Disease |
2.9% |
| Neutrophil Count Decreased |
2.9% |
| Ascites |
2.4% |
| Eosinophilia |
2.4% |
| Hepatitis |
2.4% |
| Hyperbilirubinaemia |
2.4% |
| Jaundice |
2.4% |
| Pyrexia |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
20.5% |
| Prophylaxis |
13.9% |
| Tuberculosis |
11.1% |
| Hiv Infection |
10.1% |
| Rheumatoid Arthritis |
6.7% |
| Atypical Mycobacterial Infection |
5.1% |
| Pulmonary Tuberculosis |
4.2% |
| Hypertension |
3.9% |
| Product Used For Unknown Indication |
3.0% |
| Infection |
2.8% |
| Pain |
2.8% |
| Osteitis |
2.6% |
| Unevaluable Event |
2.4% |
| Injury Corneal |
2.1% |
| Staphylococcal Infection |
2.0% |
| Cardiac Failure |
1.6% |
| Antibiotic Therapy |
1.5% |
| Crohn's Disease |
1.5% |
| Anaemia |
1.3% |
| Asthma |
1.2% |
|
| Renal Failure Acute |
13.2% |
| Pyrexia |
9.3% |
| Vomiting |
9.3% |
| Thrombocytopenia |
7.8% |
| Weight Decreased |
6.2% |
| Tachycardia |
5.4% |
| Urinary Tract Infection |
4.7% |
| Erythema |
3.9% |
| Sepsis |
3.9% |
| Stevens-johnson Syndrome |
3.9% |
| Toxic Epidermal Necrolysis |
3.9% |
| Visual Field Defect |
3.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.1% |
| Fall |
3.1% |
| Interstitial Lung Disease |
3.1% |
| Optic Neuritis |
3.1% |
| Pruritus |
3.1% |
| Renal Tubular Necrosis |
3.1% |
| Tonic Convulsion |
3.1% |
| Viral Infection |
3.1% |
|
| Interacting |
| Disseminated Tuberculosis |
48.5% |
| Hypertension |
20.0% |
| Aspergillosis |
4.6% |
| Lung Transplant |
4.6% |
| Tuberculosis |
4.6% |
| Ear Tuberculosis |
2.3% |
| Heart Transplant |
2.3% |
| Opportunistic Infection Prophylaxis |
2.3% |
| Depression |
1.5% |
| Langerhans' Cell Histiocytosis |
1.5% |
| Prophylaxis |
1.5% |
| Psychotic Disorder |
1.5% |
| Anxiety |
0.8% |
| Infection Prophylaxis |
0.8% |
| Lung Infection |
0.8% |
| Rheumatoid Arthritis |
0.8% |
| Staphylococcal Infection |
0.8% |
| Type 1 Diabetes Mellitus |
0.8% |
|
| Hypertensive Encephalopathy |
34.8% |
| Hepatic Failure |
21.7% |
| Drug Interaction |
17.4% |
| Psychiatric Decompensation |
8.7% |
| Drug Level Increased |
4.3% |
| Immunosuppressant Drug Level Decreased |
4.3% |
| Renal Failure Acute |
4.3% |
| White Blood Cell Count Increased |
4.3% |
|
